Quark Pharmaceuticals Patents
Quark Pharmaceuticals has filed 78 patents.
Molecular biology, RNA, Transcription factors, Gene expression, DNA
Molecular biology, RNA, Transcription factors, Gene expression, DNA
Latest Quark Pharmaceuticals News
Aug 24, 2022
Patrice Wendling August 24, 2022 A multi-biomarker risk score helps predict increased risk for future cardiovascular (CV) events as well as high-risk anatomy at revascularization in stable patients with atherosclerotic cardiovascular disease (ASCVD), a new FOURIER trial analysis suggests. The risk score incorporates high-sensitivity C-reactive protein (hsCRP), N-terminal pro B-type natriuretic peptide (NT-proBNP), high-sensitivity troponin I (hsTnI), and growth differentiation factor 15 (GDF-15). These routine biomarkers of inflammation and fibrosis, ventricular strain, and myocardial injury are individually associated with incident CV in stable ASCVD and were shown in earlier work to be a multi-marker score to predict CV events in patients stabilized after an acute coronary syndrome in the IMPROVE-IT trial . Validating the score, however, wasn't really the intent here, explained senior author Brian Bergmark, MD, with the TIMI Study Group, Brigham and Women's Hospital, and Harvard Medical School, Boston. "We know broadly speaking people with high troponin, BNP, et cetera, are going to have broadly defined clinical events like Mis [myocardial infarctions], death. And we also know on a granular level at a single time point that people who, for example, get a coronary CT scan and have a contemporary troponin level tend to have a little bit more coronary disease," he said. "But that leaves this broad swath of, what if we follow people over time? Can biomarkers in some form actually predict specific coronary anatomical characteristics and revascularization procedures in conjunction with clinical events?" Bergmark continued. "That's sort of an untouched link or translational step between some of the granular data and these clinical events." As published in the Journal of the American College of Cardiology, the post hoc study analyzed baseline blood samples from 21,644 FOURIER participants and adapted the previously studied multi-marker score to use hsTnI in place of high-sensitivity troponin T (hsTnT). One point was assigned for each elevated biomarker: hsCRP ≥ 2 mg/L, NT-proBNP ≥ 450 pg/mL, hsTnI ≥ 6 ng/L, and GDF-15 ≥ 1800 pg/mL. A total of 6444 patients had a low score (0 points), 12,439 an intermediate score (1-2 points), and 2761 a high score (3-4 points). Patients with higher biomarker scores were older and were more likely to have hypertension , diabetes, multiple prior MIs, heart failure , prior coronary artery bypass grafting (CABG), and peripheral artery disease but were less likely to have prior percutaneous coronary intervention (PCI). Results showed a stepwise increase in 3-year risk for major coronary events (coronary death, MI, or coronary revascularization) from 7.3% with a low score to 11.3% with an intermediate score and 21.0% with a high score. A near tripling of risk remained in those with a high score after adjustment (hazard ratio [HR], 2.90). Individuals with a high score had twice the risk for any coronary revascularization (HR, 2.10) and complex revascularization (HR, 2.07), as well as increased risks for complex PCI (HR, 1.80), CABG (HR, 2.57), and in-stent restenosis (ISR) revascularization (HR, 1.78). The study is the first to show an association of these biomarkers with future ISR revascularization in a broad cohort of patients with stable ASCVD, the investigators observe. It could be a random signal, but "it's one piece of data as people start to look at other datasets, as we start to understand who's at risk for ISR, as we understand this disease entity that's really a pandemic at this point," Bergmark said, "I think this is one piece of the puzzle that's novel." Compared with those with a low score, patients with a high biomarker score had significantly higher risks for left main disease greater than 50% (HR, 2.22; P = .003), multivessel disease (HR, 1.99; P < .001), and chronic total occlusion (HR, 2.50; P < .001) at the time of revascularization. There was no significant interaction between the biomarker score and the effect of evolocumab used in the trial; however, the assessment had limited statistical power, the authors note. Bergmark said that the results can inform trial design to select a population at risk for specific types of events and when trying to risk adjust in a population for reimbursement purposes to understand quality metrics, for example, for people coming back with ISR. "I think refining risk estimates has broad applicability clinically and academically," he added. "This is one step, with one dataset, pushing these typically broad clinical endpoints to be more specific." In an related editorial , Giles Montalescot, MD, PhD, Pitié-Salpêtrière Hospital, Paris, France, and colleagues write, "Not only does this study validate the multi-biomarker score in a new cohort of patients and with new coronary-focused outcomes, but it also opens novel and interesting avenues, on a global approach of cardiovascular risk ." Possibilities include using this or another multi-biomarker risk score to streamline enrichment or selection criteria for a trial or as a surrogate endpoint in proof-of-concept trials to test a new drug aimed at reducing CV risk. "Beyond clinical research, we could imagine in the future to base our therapeutic decisions on such a score, just like we decide anticoagulation in patients with atrial fibrillation according to the CHA₂DS₂-VASc score," the editorialists say. This being said, Montalescot and colleagues point out that the current multi-biomarker risk score assigned equal prognostic value to each of the components, whereas IMPROVE-IT and FOURIER both showed that elevated hsTnT and NT-proBNP were associated with much higher hazard ratios than hsCRP and GDF-15. Other limitations, they say, are that the categorical nature of the variables, albeit user friendly, prevent any subtle analysis; the score does not include biological risk factors; and questions remain about the impact of the lipid-lowering intervention across risk categories. FOURIER was funded by Amgen. The TIMI Study Group has received institutional grant support through Brigham and Women's Hospital from Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Bayer HealthCare Pharmaceuticals, Daiichi-Sankyo, Eisai, Intarcia, MedImmune, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron Pharmaceuticals, Roche, Siemens Healthcare Diagnostics, The Medicines Company, and Zora Biosciences. Bergmark reports grant support from Pfizer, Ionis, AstraZeneca, and Abbott Vascular; and consulting fees from Philips, Abbott Vascular, Servier, Daiichi-Sankyo, Janssen, and Quark Pharmaceuticals. Montalescot reports research grants to his institution or consulting/lecture fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cell Prothera, CSL Behring, Europa, Idorsia, IRIS-Servier, Medtronic, MSD, Novartis, Pfizer, Quantum Genomics, and Sanofi-Aventis. J Am Coll Cardiol. 2022;80:887-897, 898-901. Abstract ; Editorial Follow Patrice Wendling on Twitter: @pwendl For more from theheart.org | Medscape Cardiology, join us on Twitter and Facebook
Quark Pharmaceuticals Frequently Asked Questions (FAQ)
When was Quark Pharmaceuticals founded?
Quark Pharmaceuticals was founded in 1993.
Where is Quark Pharmaceuticals's headquarters?
Quark Pharmaceuticals's headquarters is located at 6501 Dumbarton Circle, Fremont.
What is Quark Pharmaceuticals's latest funding round?
Quark Pharmaceuticals's latest funding round is Series F.
How much did Quark Pharmaceuticals raise?
Quark Pharmaceuticals raised a total of $37M.
Who are the investors of Quark Pharmaceuticals?
Investors of Quark Pharmaceuticals include SBI Investment and Mitsubishi UFJ Capital.
Who are Quark Pharmaceuticals's competitors?
Competitors of Quark Pharmaceuticals include Vistagen, SpiroGen, OptiMedica, Angstrom Pharmaceuticals, Elevation Pharmaceuticals and 7 more.
Compare Quark Pharmaceuticals to Competitors
MedElute is a start-up based in Michigan that has been granted a paid up license from Angiotech Pharmaceutical, Inc. as part of the merger transaction between Angiotech and Afmedica, Inc. The license is for rights to a pending patent (not yet issued) in which claims are made for methods and materials to treat post surgical adhesions with a highly anti-platelet approach.
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
Charleston Laboratories, Inc is a specialty pharmaceutical company focused on the research and development of pain products that prevent or significantly reduce nausea and vomiting, the two most burdensome side effects related to opioid analgesics and other pain associated disease states.
Inverseon Overview There are over 20 million Americans living with asthma -- and the numbers continue to increase. Inverseon, Inc. is a clinical-stage company developing drugs for chronic diseases of the lung. Inverseon's asthma program has successfully completed two Phase IIa proof-of-concept human studies
ThyroChek specializes in medical diagnostics within the healthcare sector, focusing on rapid screening for thyroid-related disorders. The company offers a rapid test that detects elevated levels of thyroid stimulating hormone (TSH) in whole blood, which is an early indicator of hypothyroidism. ThyroChek's product is primarily utilized by healthcare providers to streamline the screening process and reduce unnecessary testing and expenses. It is based in San Diego, California.
Bridge Pharmaceutical aims to "bridge the gap" between the U.S. and Asia drug industries by transferring top FDA-compliant development technology to Asia.